肿瘤预防与治疗2025，Vol.38Issue(3)：231-236,6.DOI:10.3969/j.issn.1674-0904.2025.03.008
罗普司亭治疗化疗相关性血小板减少症4例暨文献复习
Romiplostim for the Treatment of Chemotherapy-Induced Thrombocyto-penia:A Report of 4 Cases and Literature Review
曾茜敏 1李明 2张豪 2赵洁珺 1席亚明2
作者信息
- 1. 730000 兰州,兰州大学第一临床医学院
- 2. 730000 兰州,兰州大学第一医院血液科
- 折叠
摘要
Abstract
Objective:To evaluate the safety and efficacy of Romiplostim in the treatment of chemotherapy-induced thrombocytopenia(CIT).Methods:Clinical data from four patients with refractory CIT treated with Romiplostim were col-lected,and a review of relevant literature was conducted.Results:All four patients experienced recurrent thrombocytopenia following chemotherapy for solid tumors,and their platelet levels improved after treatment with interleukin-11 or recombinant human thrombopoietin.Following subsequent chemotherapy,platelet levels were difficult to maintain with the aforementioned treatments.Different thrombopoietin receptor agonists were tried successively,and platelet counts eventually normalized after treatment with Romiplostim.No adverse effects were observed in these four patients treated with Romiplostim.Based on a re-view of relevant literature,the mechanism of action of Romiplostim in treating CIT is not yet fully understood,although the AKT signaling pathway may play a role.The recommended starting dose is 3 μg/kg,with a maximum dose of 10 μg/kg.Ma-intenance therapy has been shown to effectively correct CIT,enabling most patients to resume chemotherapy.Conclusion:Romiplostim is safe and effective in treating refractory CIT and can rapidly increase platelet levels in patients.关键词
化疗相关性血小板减少症/罗普司亭/疗效Key words
Chemotherapy-induced thrombocytopenia/Romiplostim/Treatment outcome分类
临床医学引用本文复制引用
曾茜敏,李明,张豪,赵洁珺,席亚明..罗普司亭治疗化疗相关性血小板减少症4例暨文献复习[J].肿瘤预防与治疗,2025,38(3):231-236,6.
